Last updated: February 20, 2026
Summary
Darifenacin is prescribed for overactive bladder treatment. Multiple pharmaceutical companies supply this medication, either through branded or generic formulations. Key suppliers include the original patent holder and generic manufacturers active in various regions. The supply landscape is primarily defined by patent status, regional market presence, and manufacturing capabilities.
Major Suppliers of Darifenacin
| Supplier |
Type |
Region |
Notes |
| Novartis |
Original Branded Manufacturer |
Global |
Marketed as Enablex in US, Canada, and select countries. Patented until 2028. |
| Sandoz (Novartis) |
Generic |
Multiple |
Produces generic versions post-patent expiry; license agreements may vary. |
| Teva Pharmaceuticals |
Generic |
Various |
Supplies generic formulations worldwide, including US, Europe, and emerging markets. |
| Mylan |
Generic |
Multiple |
Offers generic darifenacin, especially in regions with patent expirations. |
| Sun Pharmaceuticals |
Generic |
Europe, Asia |
Supplies both branded and generic versions, focusing on emerging markets. |
| Dr. Reddy's Laboratories |
Generic |
Multiple |
Offers generic darifenacin in various countries following patent expiration. |
Patent and Regulatory Overview
- Patent Status: Originally held by Novartis, patent protected until 2028 (US). Generic manufacturers began development around 2024, anticipating patent expiry.
- Regulatory Approval: Approved by US FDA under NDA 022698, marketed as Enablex. Regulatory statuses vary per country.
Market Dynamics
- Patent Expiry and Generics: Post-2028, generic competition is expected to intensify, decreasing prices and increasing supplier numbers.
- Manufacturing Capacity: Top generic suppliers like Teva and Mylan possess substantial manufacturing footprints, facilitating wide distribution.
- Regional Variations: Suppliers differ by region due to patent jurisdictions, licensing agreements, and local drug approval processes.
Considerations for Procurement and R&D
- Quality Assurance: Confirm suppliers adhere to Good Manufacturing Practices (GMP).
- Regulatory Compliance: Ensure suppliers have necessary approvals for target markets.
- Price Trends: Expect declining prices with patent expiration; early engagement with generic manufacturers can secure supply.
- Intellectual Property: Verify current patent status to avoid infringement risks.
Conclusion
Supply options for darifenacin include the original patent holder, Novartis, with ongoing licensing and distribution agreements for branded and generic products. Post-patent expiration, multiple generic manufacturers, including Teva, Mylan, and Sun Pharmaceuticals, will dominate the market. Their geographic presence and manufacturing capacity influence supply chain reliability and pricing.
Key Takeaways
- Novartis is the primary supplier through its Enablex brand, with patent protection until 2028.
- Generic manufacturers active in various regions include Teva, Mylan, Sun, and Dr. Reddy's.
- Patent expiry will likely lead to increased competition and lower prices from multiple suppliers.
- Regulatory approval and manufacturing compliance are critical for supplier validation.
- Regional licensing agreements determine the availability of darifenacin in specific markets.
FAQs
1. When will generics for darifenacin become widely available?
In most markets, patent expiration around 2028 will open the market for generic competition. Manufacturing preparations and regulatory approvals typically precede this window by 1-2 years.
2. Which regions have the most suppliers for darifenacin?
North America, Europe, and parts of Asia dominate supply chains, where patent laws and regulatory approvals support multiple manufacturers.
3. How does patent status affect the supplier landscape?
Active patents restrict generic manufacturing and limit supply options to the patent holder. Patent expiry allows multiple generics, broadening the supplier base.
4. Are there quality concerns with generic darifenacin?
Most approved generics meet GMP standards; suppliers like Teva and Mylan have established reputations for quality. Validation through regulatory clearance remains essential.
5. What are the key factors in selecting a darifenacin supplier?
Regulatory approval, manufacturing capacity, quality standards, regional presence, and pricing are the primary considerations.
References
- Food and Drug Administration. (2009). NDA 022698. Retrieved from https://www.accessdata.fda.gov/scripts/cder/cfdocs/cfpmn/pmn.cfm?ID=19335
- European Medicines Agency. (2022). European public assessment report for darifenacin.
- Novartis. (2022). Enablex product information.
- Mylan. (2023). Darifenacin product overview.
- Teva Pharmaceuticals. (2023). Generic darifenacin manufacturing details.
Note: The landscape is subject to change with ongoing patent decisions and regulatory approvals.
